MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Phase 4
Terminated
Conditions
Myocardial Injury
Interventions
First Posted Date
2014-11-14
Last Posted Date
2017-02-09
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
6
Registration Number
NCT02291419
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

VA North Texas Health Care System, Dallas, Texas, United States

and more 21 locations

Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis

Early Phase 1
Completed
Conditions
Solid Tumor
Cancer
Interventions
First Posted Date
2014-11-07
Last Posted Date
2019-05-08
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
17
Registration Number
NCT02285738
Locations
🇺🇸

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

First Posted Date
2014-11-07
Last Posted Date
2019-08-20
Lead Sponsor
Medical University of Vienna
Target Recruit Count
200
Registration Number
NCT02285751
Locations
🇦🇹

General Hospital, Vienna, Austria

Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.

Phase 2
Completed
Conditions
Fetal Growth Retardation
Premature Birth
Infant, Very Low Birth Weight
Small for Gestational Age
Preeclampsia
Interventions
First Posted Date
2014-10-31
Last Posted Date
2018-11-09
Lead Sponsor
CHU de Quebec-Universite Laval
Target Recruit Count
50
Registration Number
NCT02280031
Locations
🇨🇦

Hôpital St-François d'Assise-CHUQ, Quebec, Canada

🇨🇦

Centre Hospitalier Universitaire de Québec (CHU de Québec)/Pavillon CHUL, Québec, Canada

Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty

Phase 2
Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2014-10-22
Last Posted Date
2016-02-19
Lead Sponsor
Hanyang University Seoul Hospital
Target Recruit Count
156
Registration Number
NCT02271399
Locations
🇰🇷

Department of Orthopaedic Surgery, Hanyang University, College of Medicine, Seoul, Korea, Republic of

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Phase 4
Completed
Conditions
Cardiovascular Disease
Interventional Cardiology
Interventions
First Posted Date
2014-10-21
Last Posted Date
2021-01-13
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
9006
Registration Number
NCT02270242
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms

Early Phase 1
Completed
Conditions
Insomnia
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2014-10-20
Last Posted Date
2017-03-15
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
8
Registration Number
NCT02268565
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Phase 3
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2014-10-16
Last Posted Date
2017-10-09
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
100
Registration Number
NCT02266030
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Bundang-gu, Korea, Republic of

The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis

Not Applicable
Completed
Conditions
Hemodialysis
Interventions
First Posted Date
2014-10-09
Last Posted Date
2014-10-23
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
410
Registration Number
NCT02261025
© Copyright 2025. All Rights Reserved by MedPath